File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Results of a uniform treatment protocol based on the ALCL99 study for anaplastic large cell lymphoma in children and adolescents of Hong Kong

TitleResults of a uniform treatment protocol based on the ALCL99 study for anaplastic large cell lymphoma in children and adolescents of Hong Kong
Authors
KeywordsMedical sciences
Oncology medical sciences
Pediatrics
Issue Date2013
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 81-82, abstract no. P-0116 How to Cite?
AbstractPURPOSE/OBJECTIVE: We aim to review the results of a uniform territory-wide treatment protocol for anaplastic large cell lymphoma (ALCL) established in Hong Kong since 2000. MATERIALS AND METHODS: The five hospitals of Hong Kong forming the Hong Kong Paediatric Haematology and Oncology Study Group (HKPHOSG) established a uniform treatment protocol based on the ALCL99 study to treat children and adolescents with ALCL since 2000. The clinical data of all cases diagnosed between 1-Jan-2000 and 31-Dec-2011 were reviewed up to the date of 31-Dec-2012. RESULTS: During the study period, a total of 13 cases of ALCL were diagnosed. Eight (62%) were males. The median age was 9.4 years (range, 6.3 to 15.4 years). The median follow up duration was 5.73 years (range, 0.35 to 12.6 years). The Murphy stages consisted of 7.5% stage 1 (n = 1), 23% stage 2 (n = 3), 62% stage 3 (n = 8) and 7.5% stage 4 (n ? 1; bone marrow involvement). The sites of lymphoma included nodal and/or extranodal sites such as lung, pericardium, mediastinum, bone and skin. Two cases had skin nodules only. None had CNS involvement. Ten cases were ALK+ , one case was ALK- and 2 cases had unknown ALK status. Three cases were CD3+. Treatment groups were stratified as 46% standard risk (n = 6) and 54% high risk (n = 7). The 5-year eventfree survival (EFS) and overall survival (S) were 68.4% and 84.6%, respectively. All cases except one achieved CR1. One case died of refractory disease. Three cases had disease relapse of which 2 cases could be salvaged with stem cell transplantation and/or vinblastine treatment. CONCLUSIONS: Although EFS for ALCL was relatively low at <70%, overall survival of >80% could be achieved with salvage therapy. Future goal should aim at finding the optimal therapy for this rare lymphoma type through inter-group cooperative trials.
DescriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013
Poster Session - Lymphomas: abstract no. P-0116
Persistent Identifierhttp://hdl.handle.net/10722/193630
ISSN
2015 Impact Factor: 2.634
2015 SCImago Journal Rankings: 1.505

 

DC FieldValueLanguage
dc.contributor.authorChiang, AKen_US
dc.contributor.authorLee, Ven_US
dc.contributor.authorYuen, Hen_US
dc.contributor.authorLi, CBen_US
dc.contributor.authorLing, SCen_US
dc.contributor.authorCheuk, DKLen_US
dc.contributor.authorLee, ACWen_US
dc.date.accessioned2014-01-20T05:11:36Z-
dc.date.available2014-01-20T05:11:36Z-
dc.date.issued2013en_US
dc.identifier.citationThe 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 81-82, abstract no. P-0116en_US
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/193630-
dc.descriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013-
dc.descriptionPoster Session - Lymphomas: abstract no. P-0116-
dc.description.abstractPURPOSE/OBJECTIVE: We aim to review the results of a uniform territory-wide treatment protocol for anaplastic large cell lymphoma (ALCL) established in Hong Kong since 2000. MATERIALS AND METHODS: The five hospitals of Hong Kong forming the Hong Kong Paediatric Haematology and Oncology Study Group (HKPHOSG) established a uniform treatment protocol based on the ALCL99 study to treat children and adolescents with ALCL since 2000. The clinical data of all cases diagnosed between 1-Jan-2000 and 31-Dec-2011 were reviewed up to the date of 31-Dec-2012. RESULTS: During the study period, a total of 13 cases of ALCL were diagnosed. Eight (62%) were males. The median age was 9.4 years (range, 6.3 to 15.4 years). The median follow up duration was 5.73 years (range, 0.35 to 12.6 years). The Murphy stages consisted of 7.5% stage 1 (n = 1), 23% stage 2 (n = 3), 62% stage 3 (n = 8) and 7.5% stage 4 (n ? 1; bone marrow involvement). The sites of lymphoma included nodal and/or extranodal sites such as lung, pericardium, mediastinum, bone and skin. Two cases had skin nodules only. None had CNS involvement. Ten cases were ALK+ , one case was ALK- and 2 cases had unknown ALK status. Three cases were CD3+. Treatment groups were stratified as 46% standard risk (n = 6) and 54% high risk (n = 7). The 5-year eventfree survival (EFS) and overall survival (S) were 68.4% and 84.6%, respectively. All cases except one achieved CR1. One case died of refractory disease. Three cases had disease relapse of which 2 cases could be salvaged with stem cell transplantation and/or vinblastine treatment. CONCLUSIONS: Although EFS for ALCL was relatively low at <70%, overall survival of >80% could be achieved with salvage therapy. Future goal should aim at finding the optimal therapy for this rare lymphoma type through inter-group cooperative trials.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Canceren_US
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectPediatrics-
dc.titleResults of a uniform treatment protocol based on the ALCL99 study for anaplastic large cell lymphoma in children and adolescents of Hong Kongen_US
dc.typeConference_Paperen_US
dc.identifier.emailChiang, AK: chiangak@hku.hken_US
dc.identifier.emailLi, CB: jamesli@hku.hken_US
dc.identifier.emailCheuk, DKL: klcheuk@hkucc.hku.hken_US
dc.identifier.authorityChiang, AK=rp00403en_US
dc.identifier.doi10.1002/pbc.24719-
dc.identifier.hkuros227220en_US
dc.identifier.volume60-
dc.identifier.issueS3-
dc.identifier.spage81-
dc.identifier.epage82-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats